Keywords: scolr, develop, new, cdt, drugs, washington, usa-based
SCOLR to develop three new CDT drugs
Article | 22 April 2005
Washington, USA-based biopharmaceutical company SCOLR Pharma says it will proceed with the internal development of three additional drug targets harnessing ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- New Zealand declines Alexion's funding application for Solaris
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Elan makes "transformational" acquisitions and a divestment
